Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072930 · ClinicalTrials.gov registry record · Phase 2
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00072930 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 150 participants.
The verdict
NCT00072930, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The primary objectives of this study are: 1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer (AIPC); and 2. To summarize the safety of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in this patient population.
Interventions
- BIOLOGICAL MEDI-522
- BIOLOGICAL Docetaxel + Prednisone* + Zoledronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072930
The ClinicalTrials.gov registry entry for NCT00072930 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI-522 is the first listed.
NCT00072930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072930 about?
NCT00072930 is a clinical study titled "MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer". The primary objectives of this study are: 1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer (AIPC); and 2. To summarize the safety of MEDI-522 in combination with docetaxel...
What is the current status of trial NCT00072930?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2003-12. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00072930?
The interventions under investigation include: MEDI-522 (BIOLOGICAL), Docetaxel + Prednisone* + Zoledronic Acid (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072930?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.